Advanced Biological Laboratories (ABL) S.A. Enters into Exclusive Licensing Agreement with CRP-Santé for “COMET” Software a Tool Designed for High Performance DNA Sequencing Analysis and Classification
LUXEMBOURG–(BUSINESS WIRE)–Advanced Biological Laboratories (ABL) S.A., a Luxembourg-based company today announced that it has entered into an exclusive worldwide licensing agreement with CRP-Santé, a Luxembourg-based public research center active in the field of clinically oriented biomedical research, for its COMET (COntext-based Modeling for Expeditious Typing) software, a tool designed to rapidly analyze and optimally subtype large genetic data sets arising from epidemiological or antiretroviral resistance in the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) fields. Integrated in the clinical management and diagnostics platforms of ABL, COMET will contribute to support the decision-making of healthcare professionals in their daily challenge of providing the best treatment adapted to each of their patients with viral and other infectious or chronic diseases.
“COMET is by far the fastest tool available for the classification of viral sequences such as HIV-1/2 and HCV into subtypes or genotypes,” said Daniel Struck, bioinformatician at the Laboratory of Retrovirology in CRP-Santé who developed this software. “This advantage is recognized among the scientific community,” said Daniel Struck who referred to a publication of Pineda-Peña A.-C. and colleagues in the Journal “Infection, Genetics and Evolution” in 2013 and added that the software is freely available for non-commercial research use only through its dedicated website http://comet.retrovirology.lu.
“I think that the concept of COMET has a great potential for many applications in high-throughput sequence data analysis and that our licensing agreement with ABL will increase the visibility of CRP-Santé‘s research expertise and capabilities towards healthcare and diagnostics professionals,” said Dr. Carole Devaux, Head of the Laboratory of Retrovirology in CRP-Santé.
“We are pleased at ABL to have signed this exclusive commercial licensing agreement with CRP-Santé and to be able to promote COMET alone or embedded within ABL’s software applications,” stated Dr Chalom Sayada, CEO of ABL. “This tool is already offered in the DeepChek® software for HIV, hepatitis B virus (HBV) and HCV genomic analysis as Virology is our initial main field of applications as of today. We are working already to extend the portfolio of ABL’s offering for software managing and analyzing next generation sequencing data for microbiology and Human DNA fields such as Oncology and HLA typing,” added Dr. Sayada.
About CRP-Santé:
The Public Research Center for Health (CRP-Santé) is a public biomedical research organization based in Luxembourg. Gathering a workforce of about 250 scientists, CRP-Santé’s research activities are structured in five thematic research departments, i.e. Cardiovascular diseases, Immunology, Infection and Immunity, Oncology and Public Health. Those departments have access to key transversal expertise and technological resources organized in three competence centers, i.e. the Clinical and Epidemiological Investigation Centre (CIEC), the Competence Centre for Methodology and Statistics (CCMS) and the Luxembourg Biomedical Research Resources (LBR2) which includes six technological platforms. Striving for excellence, CRP-Santé researchers, by their creativity, enthusiasm and commitment, contribute to translation of knowledge into diagnostic and therapeutic innovations, as well as clinical applications that impact the healthcare of Luxembourg and European citizens. Learn more on: www.crp-sante.lu.
About ABL:
Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management tools, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek® and HepatiC™, which are used for data and patient management, monitoring and personalized reporting applications. In 2012, some of ABL’s products received CE-marking for IVD use. ABL’s products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions, for sequencing, clinical genotyping, and drug resistance analysis, including powerful fully integrated databases and analysis systems combining standard and high-throughput Next Generation Sequencing data. More at www.ablsa.com. All trademarks used or mentioned in this release are protected.
